Company Overview of CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of migraine headaches in adults. The company is also developing IV lasmiditan, which is in Phase II clinical trial for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts. CoLucid Pharmaceuticals, Inc. is a subsidiary of Eli Lilly and Company.
222 Third Street
Cambridge, MA 02142
Founded in 2005
Key Executives for CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
January 18, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact CoLucid Pharmaceuticals, Inc., please visit www.colucid.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.